Program Faculty
Felicia Cosman, M.D.
Endocrinologist
Helen Hayes Hospital
Osteoporosis Specialist
Associate Professor of Clinical
Medicine at Columbia University
Clinical Director of
The National
Osteoporosis Foundation
New York, NY
Production services for this monograph:
KSP Communications
140 Sherman St
Fairfield, CT 06824
(203) 259-2279
Contact KSP for additional copies.
Website Design and Development
Chris Stephens
Jeanne Schlesinger, M.Ed.
©Copyright 2002
Virginia Commonwealth University
School of Medicine, Medical College of Virginia,
Virginia Commonwealth University, Medical
College of Virginia Campus (VCU), Richmond, VA
Systems Requirements
- 233MHz Intel Pentium II processor
- 64MB of RAM
- 28.8Kbps modem (audio only)
- 16-bit sound card and speakers
- 65,000-color video display card set to display at 800x600 (video)
- Windows 98, Windows 2000, Windows ME, Windows NT 4.0 with Service Pack 4 or later, Windows XP
- IE 5.0 or later
- Add
Macromedia Flash player if not already installed
- Add
Real player if not already installed
- Add
Adobe Acrobat reader if not already installed
Faculty Disclosure
In compliance with the Standards for
Commercial Support of Continuing Medical
Education (ACCME), the following faculty
report these relationships:
Felicia Cosman, M.D.:
Grant/research support: Wyeth-Ayerst
Consultant: Merck
Speakers' bureau: Merck and Eli Lilly
Accreditation and Educational Credit
The School of Medicine, Virginia Commonwealth University
Medical College of
Virginia Campus (VCU), is accredited by the
Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing
education for physicians.
Physicians may claim up to 1.0 hour in
Type 1 or Type 2 CME on the Virginia Board
of Medicine Continued Competency and
Assessment Form required for renewal of an
active medical license.
VCU designates this educational activity for a
maximum of 1 hour in category 1 credit toward
the AMA Physicianís Recognition Award. Each
physician should claim only those hours of
credit that he/she actually spent in the educational
activity.
This educational activity was planned in
accordance with the Accreditation Council for
Continuing Medical Education Essential (ACCME)
Essential Areas and Standards.
Statement of Educational Need
This activity is designed to respond to the needs
of endocrinologists and other physicians who
treat patients with osteoporosis, by updating
their knowledge of the epidemiology, diagnosis,
and treatment of the disease, with an emphasis
on the bisphosphonates, which are the most
potent available drugs for the treatment of
osteoporosis.
Educational Objectives
After reading this monograph, listening to
the audio CD, and completing the post-test,
the participant should be able to:
-
Describe the epidemiology and impact of
osteoporosis
-
Describe available diagnostic guidelines and
techniques
-
Better understand the modes of action and
relative effectiveness of the various agents
used to treat osteoporosis
-
Choose the appropriate treatment
modalities for patients newly diagnosed
with osteoporosis
Statement of Educational Method
The educational information is presented in
a 12-page monograph and an accompanying
25-minute audio CD.
Statement of Evaluation Instrument
A 12-question multiple-choice post-test is used
as the evaluation instrument. An activity evaluation
questionnaire will be completed by each
participant.
Statement of Intended, or Target, Audience
This activity is intended for, but not limited to:
endocrinologists and other physicians who care
for patients with osteoporosis.
Instructions
To earn 1 hour of category 1 credit, listen to the
audio replay of the roundtable discussion, and read the material in this
monograph carefully. Complete the activity
evaluation and answer the post-test questions
on the accompanying questionnaire.
Send the questionnaire in the enclosed envelope to:
OCME REGISTRAR
P.O. Box 980048
Richmond, VA 23298-0048.
FAX: 804/828-7438
ATTN: OSTEO
PROGRAM.
Your credit certificate will be
returned. Participation is confidential.
Estimated program completion time: 1 hour.
Activity Number: END 00 09 102 02
Release date: 09-01-02.
Expiration date: 08-31-04.
Acknowledgement of Commercial SupportSupported by an unrestricted educational grant
from Merck & Co., Inc.
